{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029433","form_type":"8-K/A","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.579293+00:00","generated_at":"2026-06-11T06:56:49.462548+00:00","sec_items":["1.01","5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evofem Biosciences amends 8-K; annual meeting to vote on 6x share increase to 3B, notes at 8% convertible at $1.25","bullets":["Annual meeting on Sep 14, 2023; proposal to amend charter to increase authorized shares from 500M to 3B.","Notes: 8% interest (12% on default), convertible at $1.25/share, maturity Aug 4, 2026.","Registration rights agreement requires S-1 filing within 90 days of closing; 2% liquidated damages for delays.","Record date for meeting set as Aug 7, 2023; auditor ratification and advisory vote on executive comp also on ballot.","Notes are senior-subordinate obligations of Evofem, not subsidiaries; beneficial ownership limitation of 4.99% (adjustable to 9.99%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029433","json":"https://secwatch.observer/filing/0001493152-23-029433.json","markdown":"https://secwatch.observer/filing/0001493152-23-029433.md","text":"https://secwatch.observer/filing/0001493152-23-029433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223029433/0001493152-23-029433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223029433/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:56:49.462548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"83214773dd6a15906e6e07cec5c550f936e80a90","claim":"Evofem Biosciences, Inc. entered into Securities Purchase Agreement.","evidence_excerpt":".01 Material Definitive Agreement Securities Purchase Agreement. Notes The Notes will be the senior subordinate obligations of the Company and not the financial obligations of our subsidiaries.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223029433/0001493152-23-029433-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}